Gabapentin Capsule
Product Images NDC 71335-1655

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

Illustration showing the formula to calculate creatinine clearance (CLCr). The formula uses age in years, weight in kilograms, serum creatinine in mg/dl, and includes a factor for female patients. This is not a product packaging or label image.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing mean pain scores over eight weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. Gabapentin shows a decreasing trend in pain scores over time, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows time in weeks, highlighting a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10, illustrating lower scores for Gabapentin groups compared to placebo over time.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing proportions of responders in two studies. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin (GBP) 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers indicate p-values < 0.01 and < 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot graph showing the percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis. The graph compares data points from three studies labeled as STUDY a, STUDY b, and STUDY c at various daily doses ranging from 600 mg to 1800 mg.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin showing a cyclohexane ring with amino and carboxymethyl side chains attached.*

FDA Label Image

Label Image (Lbl713351655)

Gabapentin 100 mg capsule packaging label from Bryant Ranch Prepack. The label includes a comparison to Neurontin 100 mg capsule by Aurobindo Pharma Limited, lot number 1523487, and an NDC number 71335-1655-1. It specifies the capsule as white and carries storage instructions to keep at 20°-25°C (68°-77°F). A warning about potential dizziness and a reminder to keep drugs out of children's reach are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.